VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Trial Details

NCT ID
NCT03556228
Phase
PHASE1 / PHASE2
Sponsor
VM Oncology, LLC
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • VMD-928 100 mg Tablet
  • VMD-928 Tablet and Pembrolizumab (200 mg)
Locations (sample)
  • Santa Rosa, California, United States|38.44047,-122.71443
  • Hartford, Connecticut, United States|41.76371,-72.68509
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Fort Lauderdale, Florida, United States|26.12231,-80.14338
  • Pembroke Pines, Florida, United States|26.00315,-80.22394

Key Eligibility Criteria

  • #. Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma:
  • Phase 1 Dose Escalation only: Subjects with
  • (A) any advanced solid tumors of
  • Head and Neck Cancers ("HNC") (of any types),

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →